Target Name: MIR3664
NCBI ID: G100500844
Review Report on MIR3664 Target / Biomarker Content of Review Report on MIR3664 Target / Biomarker
MIR3664
Other Name(s): hsa-mir-3664 | mir-3664 | microRNA 3664 | hsa-miR-3664-5p | MicroRNA 3664 | hsa-miR-3664-3p

MIR3664: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with 10% of these individuals being affected by severe chronic pain. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and psychosomatic conditions. The management of chronic pain is a complex and multifaceted approach that requires the use of various medications, lifestyle modifications, and other therapeutic approaches.

MIR3664 is a potential drug target and biomarker that has been identified as a potential therapeutic approach for the treatment of chronic pain. In this article, we will discuss the properties of MIR3664 and its potential as a drug target and biomarker for the treatment of chronic pain.

Properties of MIR3664

MIR3664 is a small interprotein region located on the alpha-2 chain of the tensor protein alpha-2 chain complex, which is a protein complex involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. MIR3664 consists of 19 amino acid residues and has been identified as a potential drug target due to its unique structure and bioactivity.

MIR3664 has been shown to have various physiological functions, including the regulation of cell adhesion, migration, and invasion. For instance, MIR3664 has been shown to play a role in the regulation of adherens junction, which is a protein complex involved in cell-cell adhesion. MIR3664 has also been shown to be involved in the regulation of cell migration and invasion, which are critical processes for the development and progression of cancer.

In addition to its role in cell biology, MIR3664 has also been shown to have potential therapeutic properties for the treatment of chronic pain. The chronic pain experience by individuals can lead to the activation of various neural pathways involved in pain signaling. MIR3664 has been shown to interact with various pain signaling molecules, including nociceptins, opioids, and inflammatory cytokines.

Potential as a Drug Target

MIR3664 has been identified as a potential drug target for the treatment of chronic pain due to its unique structure and bioactivity. The chronic pain experience by individuals can lead to the activation of various neural pathways involved in pain signaling. MIR3664 has been shown to interact with various pain signaling molecules, including nociceptins, opioids, and inflammatory cytokines.

MIR3664 has been shown to play a role in the regulation of adherens junction, which is a protein complex involved in cell-cell adhesion. MIR3664 has also been shown to be involved in the regulation of cell migration and invasion, which are critical processes for the development and progression of cancer. These properties make MIR3664 a potential drug target for the treatment of chronic pain.

MIR3664 has been shown to have various physiological functions, including the regulation of cell adhesion, migration, and invasion. For instance, MIR3664 has been shown to play a role in the regulation of adherens junction, which is a protein complex involved in cell-cell adhesion. MIR3664 has also been shown to be involved in the regulation of cell migration and invasion, which are critical processes for

Protein Name: MicroRNA 3664

The "MIR3664 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3664 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679 | MIR3680-1 | MIR3680-2 | MIR3681 | MIR3681HG | MIR3682 | MIR3683 | MIR3685 | MIR3686 | MIR3687 | MIR3688-1 | MIR3688-2 | MIR3689A | MIR3689B | MIR3689C | MIR3689D1 | MIR3689D2 | MIR3689F | MIR369 | MIR3690 | MIR3691 | MIR3692 | MIR370 | MIR3713 | MIR3714 | MIR371A | MIR371B | MIR372 | MIR373 | MIR374A | MIR374B | MIR374C | MIR375 | MIR376A1 | MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938